Navigation Links
Nastech Announces Third Quarter 2007 Financial Results
Date:10/29/2007

d to $16.2 million, or $0.77 per share, for the prior year period. The increase in the net loss from the prior year periods is due to a combination of lower revenue and higher spending due to increased clinical activities, headcount growth, and expenses related to research and development projects. The net loss for the prior year nine month period includes a cumulative benefit from the accounting change of adopting SFAS123(R) in January 2006 of approximately $0.3 million reflecting the net cumulative impact of estimating future forfeitures in the determination of period expense for restricted stock awards, rather than recording forfeitures when they occur as permitted prior to 2006.

Research and development expenses for the current quarter increased $3.3 million to approximately $13.8 million as compared to the prior year period and increased $8.4 million to $39.4 million for the nine months ended September 30, 2007 from the prior year period. This year-to-date net increase reflects an actual increase of approximately $12.5 million in R&D expenditures, primarily due to increases in clinical activities, the number of research and development employees and related infrastructure costs. The prior year nine month period included a $4.1 million charge due to in-process R&D expenses related to our acquisition of RNAi intellectual property from Galenea Corp. in the first quarter 2006.

Selling, general and administrative expenses increased $1.6 million to approximately $5.1 million for the current quarter compared to the prior year quarter and increased $4.0 million to approximately $14.5 million for the nine months ended September 30, 2007 from the prior year period, primarily due to increases in patent and legal costs necessary to support our business model as well as our growth.

We ended the third quarter of 2007 with approximately $58.1 million in cash, cash equivalents and investments compared to $51.0 million at December 31, 2006, including $2.2 mill
'/>"/>

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 DuPont Executive Vice President James ... research advancements and product launches across the Agriculture and ... Merrill Lynch 2015 Global Agriculture Conference. ... supplies the last two years, long-term demand for agricultural ... the last decade, when demand for corn and soybeans ...
(Date:2/26/2015)... 26, 2015 On behalf of biotech ... companies, Wilentz, Goldman & Spitzer, P.A. (Wilentz) ... lawsuit against Genewiz Inc. in excess of $10 million. ... GenScript’s trade secrets, and that it improperly hired one ... an order denying motions for judgment notwithstanding the verdict, ...
(Date:2/26/2015)... , Feb. 26, 2015 The healthcare landscape ... ever-changing arena, Frost & Sullivan will host its 20 ... Executive MindXchange , March 8 to 10, at the Hilton ... Calif. This event is a platform ... leaders to discuss industry disruptions and how to succeed in ...
(Date:2/26/2015)... The Pittcon 2015 Exposition, which ... N. Morial Convention Center in New Orleans, Louisiana, ... 19, 2015) displaying products and services used by ... labs. The Exposition will offer the latest innovations ... analytical chemistry; drug discovery; nanotechnology; life sciences to ...
Breaking Biology Technology:DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3Pittcon 2015 Announces Exposition Highlights 2
... 13% sales growth in 2008. Earnings were also very,satisfactory. Growth outlook ... trends lead to new, increased targets and higher investments,to support higher ... up by 13% in local currencies (LCY), 10% in DKK, ending ... growth of 5% in LCY and 10% in DKK in the ...
... method for testing the quality of a sperm before ... of conception. , Researchers at the University of Edinburgh, ... Council), have created a way of chemically ,fingerprinting, individual ... then consider whether the sperm is healthy enough to ...
... 21 /PRNewswire-Asia-FirstCall/ -- China Bio-Immunity,Corporation (OTC Bulletin ... China-based company that develops, produces, manufactures and ... today announced that it has initiated a ... its rabies vaccines. The lots are ...
Cached Biology Technology:Novozymes Reports Strong 2008 Results 2New sperm shaker to improve IVF success 2China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines 2China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines 3
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , ... cancer, today announced that Murali Prahalad , Ph.D., president ... Medicine World Conference (PMWC) 2015: Silicon Valley, which is ... Mountain View, Calif. on January 26-28, 2015. ... Come of Age as Biomarkers." Last year, Epic Sciences was ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... upcoming RedChip Global Online CEO Conference on January 29 ... Gino Pereira , CEO of NXT-ID will present ... product, the Wocket smart wallet and its full suite ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... A new type of protein discovered by Queen’s University researchers ... as those that cause food poisoning and typhoid. , ... YihE or RdoA ?a team of professors and students from ... up possibilities for new drug development. , “Our ...
... from the Virginia Commonwealth University Massey Cancer Center ... of Cancer Research's annual meeting suggesting the potential ... leukemia (CLL). , In this study, ... of translational research, interactions between bortezomib and romidepsin ...
... found astonishing evidence that the lifelong use of two ... by four years compared to people who are monolingual. ... literature examining how lifestyle factors such as physical activity, ... in later years of life. Cognitive reserve refers to ...
Cached Biology News:Protein discovery targets antibiotic-resistant bacteria 2Canadian study shows bilingualism has protective effect in delaying onset of dementia by four years 2Canadian study shows bilingualism has protective effect in delaying onset of dementia by four years 3
COMING SOON: Anti-Mouse C5a Receptor (CD88), Clone 10/92 Monoclonal Antibody...
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Biology Products: